Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment
The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.
You may also be interested in...
A first-in-class capsid inhibitor, lenacapavir is a linchpin of Gilead’s long-term strategy in HIV treatment and prevention, but has faced regulatory setbacks in the US.
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.